We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Committees and advisory bodies (305)
- Scheduling (national classification system) (160)
- Advertising (25)
- Safety monitoring and information (23)
- COVID-19 (11)
- Medicinal cannabis hub (6)
- Sunscreens (5)
- Clinical trials (4)
- Compliance and enforcement (4)
- Shortages and supply disruptions (3)
- Legislation (2)
- Breast implant hub (1)
- Cosmetics (1)
- Import and export (1)
- Manufacturing (1)
- Prescription opioids hub (1)
Search
574 result(s) found, displaying 76 to 100
-
Corporate reportsFind out how we are managing shortages of medicines and taking action to limit their effects. Read our 2024 report.
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closing date: 23 August 2024
-
Scheduling submissionsFind out about the public submissions on scheduling matters referred to the ACMS #44, ACCS #38 and Joint ACMS-ACCS #36 meetings held in March 2024
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsCommunique from the 6th meeting of the WHPWG, 27 March 2024
-
TGA laboratory testing reportsMedicinal cannabis products are permitted to be supplied into Australia under the Special Access Scheme, by authorised prescribers, and/or for use in clinical trials.
-
Meeting statementsAdvisory Committee on Vaccines meeting statement for meeting 47, held on 31 January 2024.
-
Meeting statementsAdvisory Committee on Vaccines meeting statement for meeting 48 held on 1 May 2024.
-
Corporate reportsThis framework outlines our processes to identify and manage risk relating to breast implants.
-
Corporate reportsThis fact sheet is for healthcare practitioners to help understand the rules surrounding importation of cosmetic injectables.
-
Scheduling decisions (final)This publication is a notice of decision made by a delegate of the Secretary of the Department of Health and Aged Care under section 52D(2) of the Therapeutic Goods Act 1989, and the reasons for the decision.
-
Corporate reportsThe report cards show the progress made by the TGA in the 3 strategies that make up the Action Plan for Medical Devices.
-
Scheduling decisions (final)Read our notice of final decision to amend (or not amend) the current Poisons Standard
-
Corporate reportsFind out about the seasonal influenza vaccines available for the 2024 southern hemisphere season.
-
Meeting statementsA meeting statement from the Point-of-care Manufacturing of Medical Devices Complex Manufacturing Hubs in Healthcare Facilities Working Group is now available.
-
Meeting statementsA meeting statement from the Medical Devices Allied Health Sector Working Group is now available.
-
Scheduling decisions (final)Final decision on proposed amendments to the Poisons Standard relating to bromoxynil
-
Meeting statementsA meeting statement from the Dental Sector Working Group is now available.
-
Scheduling submissionsFind out about the public submissions on interim decisions for scheduling matters referred to the ACMS #43, ACCS #37 and Joint ACMS-ACCS #35 meetings held in November 2023
-
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closing date: 17 April 2024
-
Meeting statementsRead key points of discussion from the meeting 13 of the Medical Devices Consumer Working Group (MDCWG).
-
Meeting statementsCommunique from the meeting of the TGACC
-
Corporate reportsAn overview of the Medicines Repurposing Program's purpose and history.
-
Corporate reportsThis publication outlines our plan to transition to a paperless model for Special Access Scheme (SAS) and Authorised Prescriber (AP) submissions. From 1 July 2024 we will only accept submissions via the SAS/AP Online System.